Both psoriasis and IBD are associated with T-cell activation and production of proinflammatory cytokines, such as IL-17A, IL-23, and TNF-α, but biologics targeting IL-17A, IL-23, or TNF-α showed different therapeutic effects in psoriasis or IBD patients. Here, TNF is linked to inflammatory bowel disease.